{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:15:38Z","timestamp":1762456538122,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011608","name":"Canadian Paediatric Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vaccine.2025.127030","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:03:41Z","timestamp":1743465821000},"page":"127030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013\u20132020"],"prefix":"10.1016","volume":"55","author":[{"given":"Kevin","family":"Meesters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond S.W.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Le Saux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taj","family":"Jadavji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun K.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127030_bb0005","first-page":"12","article-title":"The host-pathogen interactions and epicellular lifestyle of Neisseria meningitidis","author":"Mikucki","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2025.127030_bb0010","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(73)90541-2","article-title":"The meningococcal carrier-rate","volume":"301","author":"Fraser","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127030_bb0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Articles Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127030_bb0020","first-page":"30","article-title":"Meningococcal disease: clinical presentation and sequelae","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127030_bb0025","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1016\/j.vaccine.2020.10.008","article-title":"Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands","volume":"38","author":"Freudenburg-de Graaf","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127030_bb0030","first-page":"611","article-title":"Meningococcal disease in North America: updates from the global meningococcal initiative","volume":"85","author":"Asturias","year":"2022","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2025.127030_bb0035","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","article-title":"Global incidence of serogroup B invasive meningococcal disease: a systematic review","volume":"15","author":"Sridhar","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127030_bb0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-018-0869-7","article-title":"MenB-FHbp meningococcal group B vaccine (Trumenba \u00ae): a review in Active immunization in individuals aged \u2265 10 years","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2025.127030_bb0045","first-page":"1","article-title":"Diversification in immunogenicity genes caused by selective pressures in invasive meningococci","volume":"6","author":"Kremer","year":"2020","journal-title":"Microb Genom"},{"key":"10.1016\/j.vaccine.2025.127030_bb0050","first-page":"733","article-title":"Serogroup B meningococcal vaccines","volume":"7","author":"Zimmer","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.vaccine.2025.127030_bb0055","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2147\/IDR.S159952","article-title":"Meningococcal group B vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B","volume":"12","author":"Rivero-Calle","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.vaccine.2025.127030_bb0060","first-page":"30","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127030_bb0065","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec","volume":"64","author":"De Wals","year":"2017","journal-title":"Canada Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2025.127030_bb0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127030_bb0075","first-page":"14","article-title":"IMPACT after 17 years: lessons learned about successful networking","author":"Scheifele","year":"2009","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2025.127030_bb0080","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.vaccine.2019.12.051","article-title":"Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp)","volume":"38","author":"Bettinger","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127030_bb0085","first-page":"3","article-title":"Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2025.127030_bb0090","first-page":"9","article-title":"Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine","author":"McNeil","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2025.127030_bb0095","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/14760584.2023.2244596","article-title":"Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness","volume":"22","author":"Borrow","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127030_bb0100","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1080\/21645515.2020.1855951","article-title":"Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy","volume":"17","author":"Fazio","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127030_bb0105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40121-020-00370-x","article-title":"4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents","volume":"10","author":"Biolchi","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2025.127030_bb0110","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.vaccine.2018.05.081","article-title":"The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci","volume":"36","author":"Harris","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127030_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1473-3099(22)00424-8","article-title":"Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1\u20139 years: two phase 2 randomised, controlled, observer-blinded studies","volume":"23","author":"Marshall","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127030_bb0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.17269\/s41997-019-00275-4","article-title":"Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada","volume":"111","author":"Breton","year":"2020","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2025.127030_bb0125","first-page":"3","article-title":"Factor H binding protein (fHbp)-mediated differential complement resistance of a serogroup C Neisseria meningitidis isolate from cerebrospinal fluid of a patient with invasive meningococcal disease","author":"Facchetti","year":"2021","journal-title":"Access Microbiol"},{"key":"10.1016\/j.vaccine.2025.127030_bb0130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H-binding protein fHbp: key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25003275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:10:27Z","timestamp":1762456227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25003275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"alternative-id":["S0264410X25003275"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013\u20132020","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127030"}}